IP Library Granted Patent US 10,052,349
Granted Patent B2
US 10,052,349 · App. 15/605,696 · Granted Aug 21, 2018

Cell preparations for extemporaneous use, useful for healing and rejuvenation in vivo

Inventors: Antoine Turzi (Mollens, CH); Donald Francois Du Toit (Western Cape, ZA)
Assignee: RegenLab USA LLC
A61K35/19A61K8/981A61K8/983A61K35/14A61K35/15A61K35/16A61K35/18A61K35/28A61K35/30A61K35/32A61K35/34A61K35/35A61K35/36A61K35/38A61K35/39A61K35/51A61K38/363A61K38/4833A61L24/0005A61L24/106A61L26/0042A61L26/0057A61L27/3691A61L27/3886A61M1/3693A61Q19/00A61Q19/08A61K2800/87A61L2430/02A61M2202/0427C12Y304/21005
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,052,349
App. No.
15/605,696
Granted
Aug 21, 2018
Kind
B2
Abstract

The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell composition preparations for use in tissue regeneration and bone regeneration and pain reduction.

Claims (54)

1. A system for preparing a cell preparation, comprising:

a first container having a cap and containing only two additives, said cap sealing said two additives in said first container, wherein said two additives are:

an anticoagulant and a thixotropic gel;

wherein said first container is a tube adapted to centrifuge whole blood, wherein said thixotropic gel is adapted to separate platelet rich plasma by forming a barrier between said platelet rich plasma and red blood cells when said first container is centrifuged for a length of time;

a second container comprising hyaluronic acid adapted to mix with said platelet rich plasma from said first container; and

an applicator device adapted to administer to a patient a cell preparation formed by mixing said platelet rich plasma from said first container and said hyaluronic acid from said second container.

2. The system of claim 1 , wherein:

said thixotropic gel comprises a polymer mixture;

said anticoagulant comprises a sodium citrate solution at 0.1 M.

3. The system of claim 1 , wherein said applicator device comprises a double syringe adapted to mix said platelet rich plasma and said hyaluronic acid to form said cell preparation at a treatment site of the patient.

4. The system of claim 1 , wherein said system is adapted to permit mixing of said platelet rich plasma and said hyaluronic acid in said second container.

5. The system of claim 1 , wherein said second container and said applicator device comprise the same device.

6. The system of claim 1 , further comprising:

phlebotomy accessories comprising a needle for drawing blood from a patient;

wherein said tube is sealed with said cap under vacuum pressure, said vacuum pressure helping to aspirate said blood from said patient when in fluid communication with said needle.

7. The system of claim 1 , further comprising a cell preparation, wherein said cell preparation comprises at least one of: dermal cells, keratinocytes, fibroblasts, melanocytes, Langerhans cells, fat cells, bone marrow cells, muscle cells, osteoblasts, chondrocytes, periosteal membrane cells, corneal cells, umbilical cord cells, Schwann cells, tendon cells, pancreas islet cells, adipocytes, adipose stem cells, corneal limbal stem cells, corneal keratinocytes, satellite stem cells, myoblast progenitor stem cells, stem cells, cartilage cells, ligament cells, connective tissue cells, and gingival cells.

8. The system of claim 7 , wherein said cell preparation further comprises at least one of: a bone filling material, an anti-aging agent, an antibacterial agent, a corticosteroid agent, an analgesia agent, an anesthetic agent, and an adrenaline.

9. A system for preparing a cell preparation, comprising:

a first container containing only two additives, wherein said two additives are an anticoagulant and a thixotropic gel;

wherein said first container is a tube adapted to centrifuge whole blood, wherein said thixotropic gel is adapted to separate platelet rich plasma by forming a barrier between said platelet rich plasma and red blood cells when said first container is centrifuged for a length of time;

a second container comprising a tissue repair agent adapted to mix with the platelet rich plasma obtained from the first container; and

an applicator device adapted to administer to a patient a cell preparation formed by mixing said platelet rich plasma from said first container and said tissue repair agent from said second container.

10. The system of claim 9 , wherein said tissue repair agent comprises a wrinkle filler.

11. The system of claim 9 , wherein said tissue repair agent comprises a hyaluronic acid.

12. A kit comprising:

the system of claim 9 ;

phlebotomy accessories comprising a needle for drawing blood from a patient.

13. The kit of claim 12 , wherein said applicator device comprises a first applicator device for said platelet rich plasma and a second applicator device for said tissue repair agent.

14. The system of claim 9 , wherein said tube is selected from:

a glass separator tube, wherein said thixotropic gel comprises a polymer mixture and said anticoagulant comprises a sodium citrate solution at 0.1 M; and

a polyethylene terephthalate separator tube, wherein said thixotropic gel comprises a polymer mixture and said anticoagulant comprises an anhydrous sodium citrate solution.

15. The system of claim 9 , wherein said thixotropic gel is adapted to separate blood such that said platelet rich plasma comprises:

platelets at a concentration of at least 300×10 9 cells/L;

white blood cells at a concentration of at least 7.0×10 9 cells/L;

fibrinogen at a concentration of at least 3 mg/L.

16. The system of claim 9 , wherein said thixotropic gel is adapted to separate blood such that said platelet rich plasma has at least 90% of plasma cells collected from said blood.

17. The system of claim 9 , wherein said thixotropic gel is adapted to separate blood such that said platelet rich plasma has a platelet concentrate containing less than 1% hematocrit.

18. A method of treating a patient, comprising:

(a) providing the system of claim 1 ;

(b) withdrawing whole blood from a patient into said first container;

(c) centrifuging said whole blood in said first container so that said thixotropic gel separates platelet rich plasma by forming a barrier between said platelet rich plasma and red blood cells, wherein said cap seals said thixotropic gel, said anticoagulant, and said whole blood in said first container during centrifugation;

(d) mixing said platelet rich plasma from said first container with said hyaluronic acid from said second container to form a cell preparation; and

(e) administering said cell preparation to said patient with said applicator device.

19. The method of claim 18 , wherein said centrifuging step (c) comprises centrifuging said first container at a force between 1500×g and 2000×g for 3 to 10 minutes.

20. The method of claim 18 , wherein said centrifuging step (c) comprises centrifuging said first container at a force of at least 1500×g for at least 8 minutes.

21. The method of claim 18 , wherein said mixing step (d) occurs at a treatment site of said patient.

22. The method of claim 18 , further comprising a step of separating said platelet rich plasma by removing half of a supernatant containing platelet poor plasma.

23. The method of claim 18 , further comprising a step of re-suspending said platelet rich plasma in said first container.

24. The method of claim 18 , further comprising admixing said platelet rich plasma with a coagulation activator, wherein said coagulation activator comprises at least one of: a thrombin activator, a fibrinogen activator, calcium, a calcium salt, CaCl 2 , CaCO 3 , CaSO 4 , sodium, batroxobin, thrombin, a thrombin enriched preparation, an autologous thrombin, and an autologous thrombin serum.

25. The method of claim 24 , wherein said platelet rich plasma and said coagulation activator are combined at a ratio of 10:1 to 10:3.

26. The method of claim 18 , wherein said administering step (e) comprises:

filling a skin scar, a wrinkle line, or a fat deficiency of said patient with said cell preparation.

27. The method of claim 18 , wherein said administering step (e) comprises:

applying a therapeutically effective amount of said cell preparation to tissue in said patient to promote tissue regeneration.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 10, 2018
From: TURZI, ANTOINE
To: REGENLAB USA LLC
Reel/Frame 045490/0245 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 19, 2017
From: TURZI, ANTOINE; DU TOIT, DONALD FRANCOIS
To: TURZI, ANTOINE
Reel/Frame 043236/0979 →
Priority Claims (1)
WO PCT/EP2006/065493 · Aug 21, 2006 · international
Continuity (4)
Continuation 15044498 · Feb 16, 2016
Continuation 14021196 · Sep 9, 2013
Continuation 12438236
Related Publication 20170258839A1 · Sep 14, 2017
Cited By (1)
US 12,440,835